James Van Der Beek was 'doing everything' for his health. One subtle symptom revealed he had stage 3 colon cancer at 46.
"I was doing everything," Van Der Beek, 48, told Business Insider. "I was doing sauna, cold plunge, weightlifting, Pilates. I would dance and also do football training."
The "Dawson's Creek" actor balanced strength training with cardio and ate mostly organic food, "doing all the biohacking things" to stay fit, he said.
Then, he started experiencing changes in his bowel movements, a common symptom of colon cancer. He stopped drinking coffee to see whether the issue would resolve itself.
"It didn't feel like a real symptom of anything," he said. "It wasn't anything that made me rush off to go get screened."
When it persisted, he got a colonoscopy. At 46, he was diagnosed with stage 3 colon cancer. He waited more than a year into treatment before sharing the news publicly in late 2024.
With his diagnosis, Van Der Beek joined an alarming number of young people being diagnosed with advanced cancers. Many, like him, had subtle symptoms and healthy lifestyles.
While he wishes he'd gotten screened sooner, he said that even in 2023, his options were more limited. It wasn't until 2024 that the Shield blood test, a test that can spot colon cancer signs from a simple blood draw, was FDA-approved.
Van Der Beek, who said he'd most likely be dealing with cancer for the rest of his life, is now a spokesperson for Guardant Health to promote the Shield blood test. His goal, he said, is to encourage people to get screened earlier, especially as colon cancer cases are rising in patients under the age of 50. He also hopes to raise awareness around symptoms and urge people to get screened as soon as they hit 45, the recommended screening age.
"The 'could have, should have' train is a black hole," Van Der Beek said. "But don't let my 'could haves' become yours. That's my biggest message."
More young people are being diagnosed with colon cancer.
Business Insider is telling their stories and helping readers understand how to prevent the disease and what could be causing the spike.
Have you or a loved one experienced cancer as a younger person? If you would like to share your story, contact Julia Pugachevsky:jpugachevsky@insider.com
A shocking start to a new life
In 2020, Van Der Beek and his family moved from Los Angeles to Austin. He took a break from acting for a few years and kept busy raising six children alongside his wife, Kimberly.
It took time to get settled. While Van Der Beek qualified for an annual colon cancer screening at 45, he said he didn't get a colonoscopy at that point because he was still sorting out his new healthcare situation. He also didn't know that the screening guidelines had changed in 2021, lowering the recommended age from 50 to 45.
Getting diagnosed with late-stage cancer in 2023 was a shock, Van Der Beek said, one he's still processing two years later. "It really took a while to set in," he said. "The reality still sets in stages; there are so many unknowns."
"All these beautiful things that I love, and I used to define myself as — a father, a provider, a husband — all that got taken away, or at least paused."
Stage 3 cancer, in which cancer cells have spread to the lymph nodes but no other organs, typically requires chemotherapy and surgery to treat.
Balancing fatherhood and work with treatment
Van Der Beek said his "lowest point" in treatment was feeling like he was losing core parts of his identity.
"All these beautiful things that I love, and I used to define myself as — a father, a provider, a husband — all that got taken away, or at least paused," he said. "I had to sit there and say, 'Well, what am I?' And it was, 'I'm still worthy of love.'"
Van Der Beek said in addition to dealing with the treatment itself, he also had to take on "the full-time job of medical portals and appointments and medication, supplements, tests — trying to organize all that."
The actor said asking for help was hard for him, even though he really needed it.
"I don't know how anyone does this alone," he said. "It's been amazing to really see my friends come through in ways that I just never allowed them to before."
A month after he publicly announced his colon cancer diagnosis in 2024, Van Der Beek appeared in "The Real Full Monty," a televised special in which he and five other male celebrities stripped to raise cancer awareness. He said filming the special was the first time he shared the news with anyone outside his inner circle.
"It was so life-affirming to see the immediate support and the empathy and just the energy that I got back from it," he said. "I think anytime you push past what's uncomfortable and you get to the other side of fear, there's always some kind of reward."
While he used to have a "very tricky relationship" with fame, he looks at it very differently now.
"It's been a real blessing, actually, because now I get people telling me they're praying for me all over the place, and I really feel like it helps and I need it, and I am grateful for it," he said. "It connects me to so many people I otherwise would never get to connect with."
He wants younger people to get screened
Colon cancer cases are rising worldwide, particularly among people around or below the recommended screening age, which the US has dropped to meet the growing rate among younger patients.
In addition to wanting to raise general awareness about when to get screened or what symptoms to look for, Van Der Beek is passionate about alternative screening options.
While colonoscopies are considered the gold standard in testing because doctors can remove precancerous polyps, they can be expensive, time-consuming, and uncomfortable, involving laxatives and anesthesia.
"I did not find a colonoscopy to be all that pleasant," Van Der Beek said. "For people who are in a job where they can't take that kind of time off of work, it can be a challenge."
Increasingly, there are less invasive at-home tests that can provide answers. For example, Cologuard and FIT are widely used at-home tests that detect the presence of cancer in stool samples.
The Shield test is a blood test performed on people of average risk who are 45 and older. If the result is positive, a colonoscopy is the next step. Shield's research found that when their blood draw was offered to patients, colon cancer screening rates more than doubled.
The tests can miss cancer or present false positives. While those chances decrease the more advanced the cancer is, the margin of error is the reason doctors recommend colonoscopies as a first line of defense.
"I would still choose a colonoscopy for myself," Dr. Tim Cannon, a medical oncologist who directs the gastrointestinal cancer program at the Inova Schar Cancer Institute, told BI in a previous story about the new industry of less invasive tests like Shield.
Caught in its earlier stages, colon cancer is very treatable. It's why Van Der Beek hopes more people get screened, however they choose to do it.
He still remembers one of his first reactions when he got diagnosed. He wondered about the best thing that could come of his situation.
"What's the thing that I'm going to look back on this in 20 years and say, 'Thank God that happened?" he said. "So what can I do to make that the case?"
So far, raising awareness has given him a lot of purpose throughout his ongoing treatment. "I've learned a lot," he said. "If I can save anyone from having to go through this, that's magic."
Read the original article on Business Insider
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Novo Nordisk Ramps Up U.S. Legal Fight Over Wegovy, Ozempic Copies
Novo Nordisk (NOVO, Financials) expanded its U.S. legal campaign against makers of unapproved versions of semaglutide the active ingredient in its blockbuster weight?loss and diabetes drugs Wegovy and Ozempic. The Danish drugmaker said Tuesday it filed 14 new lawsuits; the targets include telehealth providers, compounding pharmacies, and medical spas accused of selling compounded semaglutide under the fake guise of personalization. Warning! GuruFocus has detected 1 Warning Sign with NVO. The suits name firms such as Prism Aesthetics, Mochi Health, and Fella Health; some have also appeared in Eli Lilly's (LLY, Financials) litigation over knockoff versions of its weight?loss drug Zepbound. Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in some cases, the products allegedly contain illicit foreign?sourced active pharmaceutical ingredients. Compounders were temporarily allowed to produce semaglutide during a declared shortage; when the U.S. Food and Drug Administration ended that allowance, some companies shifted to offering personalized versions outside the approved drug label. Novo argues the approach violates state laws on corporate practice of medicine; it also raises safety concerns, as the copies have not been proven effective. Industry groups pushed back; Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said Novo's claims misrepresent the work of legitimate, state?licensed pharmacies. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
RFK Jr. cancels at least $500M in mRNA vaccine funding. What are the implications?
The Department of Health and Human Services (HHS) announced this week it is beginning a "coordinated wind-down" of federally funded mRNA vaccine development. This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment projects worth nearly $500 million. While some final-stage contracts will be allowed to be completed, no new mRNA-based projects will be initiated, the HHS said. "We reviewed the science, listened to the experts, and acted," Secretary Robert F. Kennedy Jr. said in a press release on Tuesday. "The data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate." MORE: What we know about the safety, efficacy of mRNA vaccines amid recent scrutiny Infectious disease experts told ABC News that mRNA technology has been very successful in preventing severe disease, hospitalization and deaths, especially during the COVID-19 pandemic, potentially affecting our preparedness for future pandemics. Ending mRNA vaccine development may also squash enthusiasm for technology that has been hailed as a potential promise for cancer and HIV vaccines. "It's an excellent technology. It saved millions of lives and did it in a remarkably safe manner," Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia, told ABC News. "I think it's an unscientific move, a move that goes against existing science." Affecting future pandemic preparedness Last year, the federal government awarded Moderna $176 million to help expedite the development of an mRNA-based bird flu vaccine. Earlier this year, the vaccine manufacturer received an additional $590 million to speed up the development. However, in its press release, the HHS said it was cancelling the award, which has been issued by the Biomedical Advanced Research and Development Authority, to Moderna and the University of Texas Medical Branch. Dr. Peter Hotez, a professor of pediatrics and molecular virology at Baylor College of Medicine in Houston, told ABC News the wind-down is a blow to pandemic preparedness. During the COVID-19 pandemic, mRNA technology demonstrated its ability to scale up vaccine production quickly. "The message to the companies will clearly be that they can no longer rely on the U.S. government for supporting any mRNA vaccine work, which is unfortunate, or even tragic, because the mRNA platform is one of the few that we have for pandemic threats in terms of something that we can make a vaccine for very quickly," he said. "So what, what Mr. Kennedy's and HHS' actions are doing is weakening our pandemic preparedness and weakening our biosecurity." The HHS also said it was terminating contracts with Emory University and Tiba Biotech. Researchers had been working on using mRNA technology to develop a nasal influenza vaccine. Emory has also been working on a dry powder inhaled mRNA-based treatment for influenza and COVID with TFF Pharmaceuticals, funded by BARDA. It's unclear if this is one of the 22 contracts that have been canceled. MORE: What to know about the next generation of COVID-19 vaccines Hotez said COVID-19 and influenza can have very severe consequences and that it's incorrect for Kennedy to mischaracterize them as harmless upper respiratory infections. "COVID and flu are not [only] upper respiratory infections," he said. "The reason we develop vaccines for COVID and flu is because they cause systemic illness and lower respiratory infections and cardiovascular illness. … This is part of the anti-vaccine playbook, to diminish the severity of the illness, and to say something like influenza or COVID is an upper respiratory infection, it's just very, very misleading." Cancer vaccines, HIV treatments mRNA technology has also been hailed as a potential vector for providing personalized cancer treatments and protection against HIV transmission. In February, a small preliminary study published in the journal Nature found a personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery. Additionally, a University of Florida study found an experimental mRNA vaccine paired with anticancer drugs boosted an anti-tumor response. Meanwhile, earlier this month, an early-stage clinical trial found two mRNA vaccine candidates triggered a strong immune response against HIV. Results from the trial showed that 80% of participants who received one of two vaccine candidates produced antibodies. Although antiretroviral therapy has been the standard treatment for HIV infection, and is effective in preventing transmission, it is hard to scale up worldwide due to its costs, making mRNA vaccines to be anti-HIV vaccine strategy, researchers from the U.S., Germany and Romania wrote in a commentary in June 2022. It's unclear if any of the BARDA contracts are specifically for cancer vaccines or HIV vaccine development, but Hotez said the real damage is denigrating mRNA technology. "What he's done is he's caused uncertainty among the American people about the safety and effectiveness of mRNA for any condition, including cancer," he said. "And in fact, mRNA technology is probably the most exciting technology we have now for cancer and also other non-communicable illnesses. … Even though he may not be canceling any cancer vaccine contracts through BARDA, it may have collateral deleterious in terms of squashing enthusiasm for the technology." Offit added that mRNA is not brand-new technology. mRNA was discovered independently by two teams in 1961, including French and American molecular biologists. Breakthroughs in developing mRNA vaccines began in the early 2000s, eventually leading to the development of COVID-19 vaccines in 2020. This makes the technology primed for being used in other avenues, such as cancer vaccines, Offit said. "We now know a lot about mRNA," he said. "We know a lot about its safety. We know a lot about its safety in young children, including babies. We know a lot about it regarding gene therapy. We know a lot about this safety in terms of pregnant people, where that's often not the case with new technology." Offit went on, "So you have this background of information that enables you to move forward in a number of areas, involving babies or involving pregnant women. But there was an attempt by this administration to squelch that, to sit on all that for no good reason other than a political reason." Solve the daily Crossword
Yahoo
22 minutes ago
- Yahoo
Tandem Diabetes (NASDAQ:TNDM) Exceeds Q2 Expectations But Stock Drops 17%
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q2 CY2025 results topping the market's revenue expectations , with sales up 8.5% year on year to $240.7 million. The company expects the full year's revenue to be around $1 billion, close to analysts' estimates. Its GAAP loss of $0.78 per share was significantly below analysts' consensus estimates. Is now the time to buy Tandem Diabetes? Find out in our full research report. Tandem Diabetes (TNDM) Q2 CY2025 Highlights: Revenue: $240.7 million vs analyst estimates of $237.1 million (8.5% year-on-year growth, 1.5% beat) EPS (GAAP): -$0.78 vs analyst estimates of -$0.39 (significant miss) Adjusted EBITDA: -$1.85 million vs analyst estimates of $2.34 million (-0.8% margin, significant miss) The company reconfirmed its revenue guidance for the full year of $1 billion at the midpoint Operating Margin: -21.5%, down from -13.9% in the same quarter last year Sales Volumes rose 5% year on year, in line with the same quarter last year Market Capitalization: $1.01 billion Company Overview With technology that automatically adjusts insulin delivery based on continuous glucose monitoring data, Tandem Diabetes Care (NASDAQ:TNDM) develops and manufactures automated insulin delivery systems that help people with diabetes manage their blood glucose levels. Revenue Growth Examining a company's long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Tandem Diabetes grew its sales at an impressive 19.5% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Tandem Diabetes's annualized revenue growth of 12.4% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. Tandem Diabetes also reports its number of pump shipments, which reached 21,000 in the latest quarter. Over the last two years, Tandem Diabetes's pump shipments averaged 2.9% year-on-year growth. Because this number is lower than its revenue growth, we can see the company benefited from price increases. This quarter, Tandem Diabetes reported year-on-year revenue growth of 8.5%, and its $240.7 million of revenue exceeded Wall Street's estimates by 1.5%. Looking ahead, sell-side analysts expect revenue to grow 4.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will see some demand headwinds. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Adjusted Operating Margin Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits. Tandem Diabetes's high expenses have contributed to an average adjusted operating margin of negative 7.9% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. Analyzing the trend in its profitability, Tandem Diabetes's adjusted operating margin decreased by 15.6 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers. Tandem Diabetes's adjusted operating margin was negative 13.2% this quarter. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Tandem Diabetes's earnings losses deepened over the last five years as its EPS dropped 34.2% annually. We tend to steer our readers away from companies with falling EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Tandem Diabetes's low margin of safety could leave its stock price susceptible to large downswings. In Q2, Tandem Diabetes reported EPS at negative $0.78, down from negative $0.47 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Tandem Diabetes to improve its earnings losses. Analysts forecast its full-year EPS of negative $3.09 will advance to negative $1.00. Key Takeaways from Tandem Diabetes's Q2 Results It was encouraging to see Tandem Diabetes beat analysts' revenue expectations this quarter. On the other hand, its EPS missed and its sales volume fell short of Wall Street's estimates. Overall, this was a softer quarter. The stock traded down 17% to $12 immediately after reporting. Tandem Diabetes may have had a tough quarter, but does that actually create an opportunity to invest right now? If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Inicia sesión para acceder a tu cartera de valores